Friday, 2 October 2020
One of the more dynamic partners of OptiBiotix Health Plc (OPTI), Seed Health Inc of the USA has another blockbuster project underway which is aimed at treating Irritable Bowel Syndrome (IBS). Moreover, like their first symbiotic, which is reportedly had a 400% surge in sales since July 2019, also contains OptiBiotix LP-LDL®.
"Given the valuation of pharma companies in this area (particularly the USA), this is excellent news for investors and sets the scene for LP-LDL to be used in other drug applications. It also further validates our approach to take a more rigorous and scientific approach than traditional probiotic companies to open up a wider range of opportunities and create real product differentiation. The use of LPLDL in pharma enhances the credibility of the product in the other markets. We can see an increased use for LPLDL in pharma now that we have FDA GRAS, and pharmaceutical GMP manufacture validation."
I pointed of a bleeding obvious, in that FDA approval is very significant game-changing news, to Stephen O'Hara; Yes, this is very significant news. I hope people can see that we are building up multiple opportunities and within areas like SlimBiome® and LP-LDL® building the science and regulatory approvals to open up multiple markets in food, dairy, medical foods and of course pharma (riskier but a shot to nothing as others are paying). Add to that the microbiome modulators and our 3 SweetBiotix programs, and you can see the scale of the opportunity."
GRAS is a United States Food and Drug Administration (FDA) designation that any substance added to food is considered safe by experts. GRAS status is therefore required for the use of these substances in foods. In the case of probiotics, it is a strain-specific process in which all strains not described before 1958 – as is the case of LPLDL® - must be categorised as GRAS if they are to be added to foods. GRAS assessment involves submitting an extensive technical dossier for evaluation by an independent panel of experts. They confirm if the ingredient is safe, under what conditions it can be used, and for which applications.
- 9.20 Stephen presents SlimBiome
- 13.20 Stephen explains the growth of SlimBiome in 149 countries
The market is asleep where OptiBiotix is concerned. Currently, only fully paid up members of the OptiBiotix club seem capable of looking under the bonnet and seeing there as V12 under the bonnet, not a two-stroke lawnmower engine. With larger and larger partners developing new products in 170 countries, it sure follows our time will come. The question you should be asking yourself, do I have enough and should I stop trading it and keep what I have? How much derisking against Brexit, and or COVID-19 do you need? This is very different from a single technology, single product investment, as risks are spread, and opportunities are large. The only real risk associated with OptioBiotix is boredom or the products not selling. The latter is mitigated with carefully selected companies with a history of multi-year growth, plus the human biome is a hotbed of activity now, more so due to the pandemic. Unlike so many companies banging the COVID-19 drum, OptiBiotix BOD has barley beaten the tambourine. It is almost as though the company is seeking to take care of the world poor health by stealth.
For now, I am preaching to the converted. Wider acknowledgement of OptiBiotix is needed. Maybe when OptiBiotix blows the doors off revenue expectations, we will see this happen. That, or an RNS of a blockbuster deal that is written on a keyboard with numbers on it. This is where you come in...share via the forums, SM platforms.